NEW YORK (GenomeWeb News) – Epigenomics and VSA Alta Complejidad today announced that VSA has been approved to market Epigenomics' Epi proColon kit in Argentina.

The companies have worked together since last year to secure regulatory approval for Epigenomics' blood-based colorectal cancer test from ANMAT, which regulates diagnostic tests in Argentina. They also said that VSA has forged relationships with leading diagnostic reference laboratories in Argentina to make Epi proColon available there.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.